Document Detail


Efaroxan, an alpha-2 antagonist, in the treatment of progressive supranuclear palsy.
MedLine Citation:
PMID:  9686773     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
We have tested, in a prospective randomized, double-blind, placebo-controlled, crossover, 12-week study, the effects of 2 mg efaroxan, a potent alpha-2 antagonist, given three times per day to 14 patients with progressive supranuclear palsy. Efaroxan did not induce any significant change on any motor assessment criteria. The present data do not confirm the assumption that the blockade of alpha-2 receptors might be a useful pharmacologic strategy to improve patients with progressive supranuclear palsy.
Authors:
O Rascol; K Sieradzan; H Peyro-Saint-Paul; C Thalamas; C Brefel-Courbon; J M Senard; P Ladure; J L Montastruc; A Lees
Related Documents :
16916433 - Agentic extraversion modulates the cardiovascular effects of the dopamine d2 agonist br...
22135743 - The pparγ agonist rosiglitazone is antifibrotic for scleroderma lung fibroblasts: mecha...
15866043 - Anterograde axonal transport of bdnf and nt-3 by retinal ganglion cells: roles of neuro...
Publication Detail:
Type:  Clinical Trial; Journal Article; Randomized Controlled Trial    
Journal Detail:
Title:  Movement disorders : official journal of the Movement Disorder Society     Volume:  13     ISSN:  0885-3185     ISO Abbreviation:  Mov. Disord.     Publication Date:  1998 Jul 
Date Detail:
Created Date:  1998-10-28     Completed Date:  1998-10-28     Revised Date:  2004-11-17    
Medline Journal Info:
Nlm Unique ID:  8610688     Medline TA:  Mov Disord     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  673-6     Citation Subset:  IM    
Affiliation:
Department of Clinical Pharmacology, University Hospital, Toulouse, France.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adrenergic alpha-Antagonists / adverse effects,  therapeutic use*
Adult
Aged
Benzofurans / adverse effects,  therapeutic use*
Cross-Over Studies
Dose-Response Relationship, Drug
Double-Blind Method
Drug Administration Schedule
Female
Humans
Imidazoles / adverse effects,  therapeutic use*
Male
Middle Aged
Neurologic Examination / drug effects
Prospective Studies
Supranuclear Palsy, Progressive / diagnosis,  drug therapy*,  physiopathology
Treatment Outcome
Chemical
Reg. No./Substance:
0/Adrenergic alpha-Antagonists; 0/Benzofurans; 0/Imidazoles; 89197-32-0/efaroxan

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Dysfunction of Ib (autogenic) spinal inhibition in patients with progressive supranuclear palsy.
Next Document:  Normal frontal perfusion in patients with frozen gait.